Antigenics - niemand investiert?? - 500 Beiträge pro Seite

[05836]

Erstaunlich, daß hier so wenig über Antigenics berichtet
wird. Dabei entwickelt die Firma mit Oncophage eine
sehr aussichtsreiche Vahzine gegen das Melanom und
hat dafür den "Fast Track" Status der FDA erhalten.
Ich habe mir schon wegen der interessanten Chartsituation
mal ein paar Stücke gekauft.

[puhvogel]

Ich bin nicht investiert, aber die Technologie dahinter finde ich schon sehr, sehr spannend. Ich bin in Form von Vasogen darin investiert.
Mein Problem mit Antigenics ist, dass mit 450 Millionen $ Marktkapitalisierung schon einiges vorausgesetzt wird.
Oft aber lockt Geld aber weiteres Geld an, insofern gebe ich dir recht. Was reizt dich am aktuell am Chart von der technischen Seite her?

[05836]

Im Dollar-Chart könnte sich ein Doppel-Tief bilden und
der MACD hat sehr niedriege Werte erreicht. Zudem liefert
der Slow-Stochastik m.E. ein Kaufsignal.

[puhvogel]

Momentan versuchen einige VC-Firmen die relativ günstige Periode zu nutzen um endlich Kapital am Markt aufzunehmen.
Dies erklärt auch die relative Underperformance der Biotechs der letzten Wochen.

Zitat aus dem Inplay:
08:46 ET Two biotech/pharma IPOs price at low end of range : A couple of biotech/pharma IPOs will begin trading this morning. CancerVax (CNVX 12.00), a biotech company focusing on the treatment of cancer, prices its 6 mln share IPO at $12, at the low end of the expected $12-$14 range. Lehman is the lead underwriter. Myogen (MYOG 14.00), a biopharmaceutical company focusing on the development of small molecule therapeutics for the treatment of cardiovascular disease, prices its 5 mln share IPO at $14, also at the low end of the expected $14-$16 range. CSFB is the lead underwriter... The biotech/pharma IPO market has recently suffered a couple of setbacks in addition to the low end pricings of these deals. In the past week, another IPO, Aderis Pharmaceuticals (ADPX) postponed its IPO until market conditions improve. Also, specialty drugs firm Acusphere (ACUS 9.85) went public on October 8 and is already 30% below its offering price and 39% below its opening price. Recent reports of poor clinical data and stock downgrades have dampened the sector recently. Supply exceeding demand may also be a contributing factor as investors know they can be choosy as 14 of the 50 IPOs set to price this quarter are bio/pharm companies.

[ASICS]

also ich bin auch schon ein weilchen dabei,aber über den kursverlauf enttäuscht.
ich finde die pipline toll,ich denke mit geduld wird man da mal belohnt.man hat 2 mal den fast truck einmal gegen
das melanom, und für die behandlung von nierenkrebs.
ein medikament haben sie auch schon am markt nur der kurs bewegt sich nicht.

[BrauchGeld]

HI

WEIß jemand wieviel Geld die noch zur verfügung haben ?
Danke

Gruss
M.B.

[ASICS]

FDA Lifts Clinical Hold on Antigenics’ Phase III Trials of Oncophage
Patient Enrollment Allowed to Resume Immediately
NEW YORK — November 24, 2003 — Antigenics Inc. (NASDAQ: AGEN) announced today that the US Food and Drug Administration (FDA) has lifted the partial clinical hold on the two Phase III clinical trials of the company’s personalized cancer vaccine Oncophage® (HSPPC-96). The agency’s decision to lift the hold comes 13 weeks after its request for product characterization information in September 2003.

Antigenics will immediately resume patient enrollment in its Phase III trials of Oncophage.

“Our team worked hard to provide the information within our targeted timelines,” said Garo H. Armen, PhD, chairman and CEO of Antigenics. “We are grateful for the FDA’s rapid and thorough review of our submission.”

The FDA had placed two Antigenics studies on partial clinical hold to review product characterization data. All other Oncophage trials, including Phase I and II studies, were unaffected by the hold.

Antigenics is working to develop personalized immunotherapeutics and revolutionary treatments for cancers, infectious diseases and autoimmune disorders.

This press release contains forward-looking statements, including statements regarding resuming patient enrollment for Antigenics’ Phase III trials of Oncophage. These statements are subject to risks and uncertainties that could cause actual results to differ materially to those projected in these forward-looking statements. These risks and uncertainties include, among other factors, any negative impact the partial clinical hold may have had on the willingness of physicians and patients to participate in the trials, any further regulatory actions that delay the trials, and the factors related to the regulatory approval process described in the company’s periodic filings with the Securities and Exchange Commission. Please see the “Factors That May Impact Future Results” section of the Management`s Discussion and Analysis of Financial Condition and Results of Operations in the Antigenics Quarterly Report on Form 10-Q for the quarter ended September 30, 2003, for a full discussion of these and other risk factors. Antigenics cautions investors not to place significant reliance on the forward-looking statements contained in this press release. These statements speak only as of the date of this document, and Antigenics undertakes no obligation to update or revise the statements. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.




CONTACTS
Media: Sunny Uberoi, 212.994.8206 or 917.443.3325
Investors: Tanya Sripanich, 212.994.8266


Products & Technologies | Clinical Trials | Newsroom | Investors | Jobs | About Antigenics
Copyright © 2003 Antigenics Inc. All rights reserved. Privacy Policy plus heute die nachricht: